Last week, the Patent Trial and Appeal Board (PTAB) made a partly split decision in relation to a patent review petition filed by Parse Biosciences Inc. The board denied Parse’s petition challenging a patent belonging to its genomic sequencing competitor, 10x Genomics Inc. This decision comes after PTAB had previously agreed to review a second patent that 10x Genomics had accused Parse of infringing.
This legal wrangle provides a snapshot of the tensions often encountered in the competitive genomic sequencing field: two rivals, 10x Genomics and Parse Biosciences, embedded in a profound patent dispute.
It is worth noting that the decision to deny the review represents a crucial development in this legal dispute between the two companies, which are both prominent figures in the genomic sequencing industry.
Interestingly, this PTAB decision has been delivered in a split manner, reflecting the fact that the board had previously chosen to review another patent under contention between the two rivals.
For more detailed information on this topic, visit Law360.